Tearsheet

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 46%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 42%

Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -25%

Megatrend and thematic drivers
Megatrends include Aging Population & Chronic Disease, E-commerce & Digital Retail, and Digital Health & Telemedicine. Themes include Geriatric Care, Show more.

Weak multi-year price returns
2Y Excs Rtn is -106%, 3Y Excs Rtn is -101%

Debt is significant
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 186%

Not cash flow generative
FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -1.0%

High stock price volatility
Vol 12M is 101%

Key risks
SLQT key risks include [1] a U.S. Show more.

0 Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 46%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 42%
1 Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -25%
2 Megatrend and thematic drivers
Megatrends include Aging Population & Chronic Disease, E-commerce & Digital Retail, and Digital Health & Telemedicine. Themes include Geriatric Care, Show more.
3 Weak multi-year price returns
2Y Excs Rtn is -106%, 3Y Excs Rtn is -101%
4 Debt is significant
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 186%
5 Not cash flow generative
FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -1.0%
6 High stock price volatility
Vol 12M is 101%
7 Key risks
SLQT key risks include [1] a U.S. Show more.

Valuation, Metrics & Events

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

SelectQuote (SLQT) stock has lost about 25% since 1/31/2026 because of the following key factors:

1. Downward Revision of Full-Year Guidance: Despite reporting second-quarter fiscal year 2026 earnings that surpassed analyst expectations with an EPS of $0.26 against a forecasted $0.22, and revenue of $537 million versus an anticipated $531.93 million, SelectQuote's stock experienced a significant decline. This negative market reaction was primarily due to the company cutting its full-year adjusted EBITDA guidance to a range of $90-$100 million. This revision, partly influenced by changes in a key carrier's marketing budget and pressure from PBM reimbursement rates on its Healthcare Services segment (which saw adjusted EBITDA fall to $0.8 million from $2 million in Q2 FY25), led to a pre-market stock decline of 4.14% and 6.83%.

2. NYSE Continued Listing Standard Notice: On March 25, 2026, SelectQuote received a notice from the New York Stock Exchange (NYSE) indicating non-compliance with its continued listing standards. This was because the average closing price of the company's common stock had fallen below $1.00 per share over a consecutive 30 trading-day period. The stock was trading near $0.99 around April 28, 2026, signaling significant concerns about the company's valuation and potential operational health.

Show more
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The -25.4% change in SLQT stock from 1/31/2026 to 5/21/2026 was primarily driven by a -48.9% change in the company's P/E Multiple.
(LTM values as of)13120265212026Change
Stock Price ($)1.421.06-25.4%
Change Contribution By: 
Total Revenues ($ Mil)1,5631,6425.0%
Net Income Margin (%)3.9%5.6%41.9%
P/E Multiple4.32.2-48.9%
Shares Outstanding (Mil)186189-1.9%
Cumulative Contribution-25.4%

LTM = Last Twelve Months as of date shown

Market Drivers

1/31/2026 to 5/21/2026
ReturnCorrelation
SLQT-25.4% 
Market (SPY)7.6%39.5%
Sector (XLF)-2.7%27.3%

Fundamental Drivers

The -49.0% change in SLQT stock from 10/31/2025 to 5/21/2026 was primarily driven by a -72.9% change in the company's P/E Multiple.
(LTM values as of)103120255212026Change
Stock Price ($)2.081.06-49.0%
Change Contribution By: 
Total Revenues ($ Mil)1,5271,6427.6%
Net Income Margin (%)3.1%5.6%79.6%
P/E Multiple8.12.2-72.9%
Shares Outstanding (Mil)184189-2.8%
Cumulative Contribution-49.0%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2025 to 5/21/2026
ReturnCorrelation
SLQT-49.0% 
Market (SPY)9.5%35.8%
Sector (XLF)-0.4%28.5%

Fundamental Drivers

The -66.6% change in SLQT stock from 4/30/2025 to 5/21/2026 was primarily driven by a -67.3% change in the company's P/S Multiple.
(LTM values as of)43020255212026Change
Stock Price ($)3.171.06-66.6%
Change Contribution By: 
Total Revenues ($ Mil)1,4571,64212.7%
P/S Multiple0.40.1-67.3%
Shares Outstanding (Mil)172189-9.3%
Cumulative Contribution-66.6%

LTM = Last Twelve Months as of date shown

Market Drivers

4/30/2025 to 5/21/2026
ReturnCorrelation
SLQT-66.6% 
Market (SPY)35.5%27.6%
Sector (XLF)7.7%26.2%

Fundamental Drivers

The 0.0% change in SLQT stock from 4/30/2023 to 5/21/2026 was primarily driven by a 83.4% change in the company's Total Revenues ($ Mil).
(LTM values as of)43020235212026Change
Stock Price ($)1.061.060.0%
Change Contribution By: 
Total Revenues ($ Mil)8951,64283.4%
P/S Multiple0.20.1-37.9%
Shares Outstanding (Mil)166189-12.1%
Cumulative Contribution0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

4/30/2023 to 5/21/2026
ReturnCorrelation
SLQT0.0% 
Market (SPY)85.6%30.4%
Sector (XLF)63.7%31.5%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
SLQT Return-56%-93%104%172%-62%-26%-95%
Peers Return-67%-63%15%78%1%-40%-85%
S&P 500 Return27%-19%24%23%16%9%98%

Monthly Win Rates [3]
SLQT Win Rate50%17%50%50%42%60% 
Peers Win Rate30%30%55%60%48%32% 
S&P 500 Win Rate75%42%67%75%67%60% 

Max Drawdowns [4]
SLQT Max Drawdown-76%-94%-65%-58%-78%-66% 
Peers Max Drawdown-77%-81%-59%-44%-53%-53% 
S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: EHTH, GOCO, EVER, LMND, HIPO.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/21/2026 (YTD)

How Low Can It Go

EventSLQTS&P 500
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-36.2%-9.5%
  % Gain to Breakeven56.6%10.5%
  Time to Breakeven150 days24 days
2023 SVB Regional Banking Crisis
  % Loss-52.9%-6.7%
  % Gain to Breakeven112.3%7.1%
  Time to Breakeven22 days31 days

Compare to EHTH, GOCO, EVER, LMND, HIPO

In The Past

SelectQuote's stock fell -8.3% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 9.0% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

EventSLQTS&P 500
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-36.2%-9.5%
  % Gain to Breakeven56.6%10.5%
  Time to Breakeven150 days24 days
2023 SVB Regional Banking Crisis
  % Loss-52.9%-6.7%
  % Gain to Breakeven112.3%7.1%
  Time to Breakeven22 days31 days

Compare to EHTH, GOCO, EVER, LMND, HIPO

In The Past

SelectQuote's stock fell -8.3% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 9.0% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About SelectQuote (SLQT)

SelectQuote, Inc. operates a technology-enabled, direct-to-consumer distribution platform that sells a range of insurance policies to consumers from various insurance carriers in the United States. The company operates through three segments: Senior; Life; and Auto & Home. It distributes senior health policies, such as medicare advantage, medicare supplement, medicare part D, and other ancillary senior health insurance related policies, including prescription drugs, dental, vision, and hearing plans; term life policies; and non-commercial auto and home property, and casualty policies. The company was incorporated in 1999 and is headquartered in Overland Park, Kansas.

AI Analysis | Feedback

Here are 1-3 brief analogies for SelectQuote (SLQT):

  • Expedia for insurance

  • LendingTree for insurance

AI Analysis | Feedback

  • Senior Health Insurance: Offers various health policies for seniors, including Medicare Advantage, Medicare Supplement, Medicare Part D, and other ancillary plans like prescription drug, dental, vision, and hearing coverage.
  • Term Life Insurance: Distributes life insurance policies that provide coverage for a specific period, paying a benefit upon the insured's death within that term.
  • Auto & Home Insurance: Sells non-commercial property and casualty insurance policies designed for personal vehicles and residential homes.

AI Analysis | Feedback

SelectQuote, Inc. (SLQT) sells primarily to individuals.

The company serves the following categories of customers:

  1. Seniors: Individuals seeking senior health policies, including Medicare Advantage, Medicare Supplement, Medicare Part D, and other ancillary senior health insurance policies (e.g., prescription drugs, dental, vision, and hearing plans).
  2. Individuals/Families seeking Life Insurance: Consumers interested in purchasing term life insurance policies.
  3. Individuals/Households seeking Property & Casualty Insurance: Customers looking for non-commercial auto and home property and casualty policies.

AI Analysis | Feedback

UnitedHealth Group (UNH)

Humana Inc. (HUM)

CVS Health Corporation (CVS)

The Cigna Group (CI)

Centene Corporation (CNC)

The Progressive Corporation (PGR)

The Travelers Companies, Inc. (TRV)

MetLife, Inc. (MET)

Prudential Financial, Inc. (PRU)

AI Analysis | Feedback

Timothy "Tim" Danker | Chief Executive Officer

Timothy Danker has served as CEO of SelectQuote since 2017. Prior to his current role, he held various leadership positions within SelectQuote, including President of the Life division (2016-2019), Executive Vice President of the Life division (2015-2016), and President of the Auto & Home division (2012-2015). Before joining SelectQuote, he co-founded and served as Chief Executive Officer of Spring Venture Group, a direct-to-consumer insurance brokerage, from 2007-2012.

Ryan Clement | Chief Financial Officer

Ryan Clement was appointed Chief Financial Officer in February 2023, after serving as interim CFO since May 2022. Prior to joining SelectQuote in January 2022, he was the CFO of Sifted (formerly VeriShip), a SaaS-based logistics software company. He also gained experience over seven years at Edelman Financial Engines, a Registered Investment Advisory firm, where he held various senior-level finance and operational roles. He also worked at The Mutual Fund Store.

Bob Grant | President of SelectQuote

Bob Grant has served as President of SelectQuote since 2021. His prior roles at the company include President of the Senior division (2019-2021), Chief Revenue Officer (2017-2019), Senior Vice President of Sales of the Life division (2016-2017), and Director of Sales and Operations for the Senior division (2013-2016).

William "Bill" Grant III | Chief Operating Officer

William Grant III has served as Chief Operating Officer of SelectQuote since 2019. Before this, he was Chief Marketing Officer and President of the Senior division from 2017-2019. He also served as Senior Vice President of Marketing for the Senior division for five years.

Trevor Nohe | Chief Business Officer

Trevor Nohe has served as Chief Business Officer at SelectQuote since 2022, following his role as Executive Vice President of Marketing. Prior to joining SelectQuote in 2020, he was the CEO of Inside Response for five years. He also served as CEO of Inside Academics and gained experience as a management consultant for Deloitte Consulting and as a private equity investor at Five Elms Capital.

AI Analysis | Feedback

Key Risks to SelectQuote (SLQT)

  1. Regulatory and Legal Scrutiny: SelectQuote faces significant risk from regulatory and legal challenges, primarily highlighted by a lawsuit filed by the U.S. Department of Justice (DOJ) alleging violations of the False Claims Act. This lawsuit concerns deceptive sales practices related to Medicare Advantage plans, including accusations of steering beneficiaries towards higher-commission plans rather than those most suitable for their needs. This legal action has already led to a substantial decline in the company's stock price and an investor class-action lawsuit. Continued non-compliance or adverse outcomes from regulatory reviews by entities like state insurance departments and the Centers for Medicare & Medicaid Services (CMS) could severely impact the Senior segment, which is a core part of its business.
  2. Dependence on Carrier Relationships and Industry Headwinds: The company's business model is heavily reliant on its relationships with insurance carriers and the commissions received for policy sales. SelectQuote has experienced headwinds such as significant cuts in strategic marketing budgets by national carriers, directly impacting its revenue guidance. Changes in Pharmacy Benefit Manager (PBM) reimbursement rates also present a challenge to EBITDA, even with new agreements in place. Furthermore, higher-than-usual rates of plan cancellations by carriers create a volatile and disruptive market environment, affecting policy retention and sales. Insurers prioritizing profitability could lead to further pressure on commission rates, eroding SelectQuote's margins.
  3. Profitability and Financial Stability: SelectQuote has faced scrutiny over its financial stability, characterized by a significant dependence on debt financing, as indicated by a debt-to-equity ratio of 2.27 (as of May 2025). Despite recent revenue growth, the company's net income guidance has shown a wide range, at times including potential losses, making consistent profitability a key concern. The business requires high upfront investments in agent training and marketing to generate revenue, contributing to historically tight operating margins. Analysts have also forecasted a significant decline in earnings over the next few years.

AI Analysis | Feedback

The clear emerging threat for SelectQuote (SLQT) is the rapid advancement and adoption of artificial intelligence (AI) and sophisticated data analytics, empowering both new Insurtech entrants and established insurance carriers to offer highly personalized, fully automated, and potentially unbiased direct-to-consumer platforms for insurance advice and sales. This development, alongside the growing trend of "embedded insurance" where policies are offered seamlessly at the point of sale (e.g., car insurance at the time of vehicle purchase, home insurance integrated into mortgage applications), directly disintermediates traditional insurance distribution platforms like SelectQuote by providing consumers with alternative, potentially more efficient, and often direct purchasing channels.

AI Analysis | Feedback

Here are the addressable market sizes for SelectQuote's main products and services in the U.S. region:

Senior Health Policies

  • Medicare Advantage: Enrollment in Medicare Advantage plans in the U.S. reached 34.1 million beneficiaries in 2025, representing 54% of all eligible Medicare individuals. This enrollment further grew to 35.4 million beneficiaries by February 2026, making up 51% of the Medicare population. The global Medicare Advantage market size was estimated at USD 445,973.08 million in 2025 and is projected to expand to USD 1,060,037.74 million by 2034, growing at a CAGR of 10.1%.
  • Medicare Supplement (Medigap): The U.S. Medicare Supplement health insurance market size was valued at USD 26.97 billion in 2022. It is projected to reach USD 39.26 billion by 2030, growing at a compound annual growth rate (CAGR) of 5.0% from 2023 to 2030. Another estimate places the market size at USD 30.55 billion in 2025, with a projection to reach USD 50.33 billion by 2035, growing at a CAGR of 5.10% from 2026 to 2035.
  • Medicare Part D: More than 56 million people were enrolled in Medicare Part D as of February 2026. This includes beneficiaries in stand-alone prescription drug plans (PDPs) and Medicare Advantage prescription drug plans (MA-PDs). In 2025, enrollment in stand-alone PDPs was 23 million, while close to 32 million enrollees received Part D drug coverage through Medicare Advantage plans.

Term Life Policies

  • U.S. Group Level Term Insurance: The U.S. Group Level Term Insurance Market was valued at USD 7.32 billion in 2024 and is projected to reach USD 10.57 billion by 2030, with a CAGR of 6.50%. Term life insurance is the most widely preferred choice in the United States, with 48% of households holding a term life policy. The global term insurance market was valued at USD 1.88 trillion in 2024 and is expected to reach approximately USD 4.42 trillion by 2034, growing at a CAGR of 8.92% from 2025 to 2034.

Non-Commercial Auto & Home Property and Casualty Policies

  • U.S. Personal Auto Insurance: Private-passenger auto insurance brought in approximately USD 344 billion by March 3, 2025. Personal auto insurance premiums were about USD 318 billion in 2023. Direct written premiums in personal auto grew to USD 359 billion in 2024. The United States Motor Insurance Market size, which includes personal and commercial, is projected to be USD 487.65 billion in 2025 and USD 532.45 billion in 2026, reaching USD 826.30 billion by 2031, growing at a CAGR of 9.19% from 2026 to 2031. Personal motor insurance held 76.35% of the U.S. motor insurance market in 2025.
  • U.S. Homeowners Insurance: Null

AI Analysis | Feedback

Expected Drivers of Future Revenue Growth for SelectQuote (SLQT)

SelectQuote, Inc. (SLQT) is anticipated to drive future revenue growth over the next 2-3 years through several key initiatives and operational improvements across its segments:

  1. Growth of the Healthcare Services Segment (SelectRx): The Healthcare Services segment, including its SelectRx pharmacy services, has been a significant contributor to consolidated revenue growth and is expected to continue its strong upward trajectory. The company projects increased margins and cash flow contributions as this segment scales.
  2. Enhanced Agent Productivity and Retention in the Senior Segment: SelectQuote is focused on improving agent efficiency and optimizing marketing strategies to boost productivity in its Senior health policies segment. High retention rates among tenured agents, particularly for the Annual Enrollment Period (AEP), are expected to drive policy production and, consequently, revenue.
  3. Expansion of the Life Insurance Business: The Life segment has consistently demonstrated revenue growth, with particular strength noted in term life and final expense policies. This consistent performance is expected to contribute to overall revenue expansion.
  4. Leveraging Technology and Automation for Customer Acquisition: The company emphasizes the use of technological advancements and automation to enhance operational efficiency. This focus aims to reduce variable costs and accelerate customer acquisition across its direct-to-consumer platform, enabling more efficient and scalable revenue generation.
  5. Stability from New PBM Agreements for SelectRx: Despite experiencing some short-term pressures from Pharmacy Benefit Manager (PBM) reimbursement rates, SelectQuote is actively securing new multi-year agreements with its PBM partners for the SelectRx business. These agreements are expected to provide rate predictability and better financial stability, thereby supporting the continued growth and profitability of the Healthcare Services segment.

AI Analysis | Feedback

Share Repurchases

No significant share repurchases were reported or authorized for SelectQuote (SLQT) over the last 3-5 years. The buyback coverage ratio was 0.0x for the last 12-month period, indicating an absence of substantial buyback activity.

Share Issuance

  • In February 2025, SelectQuote completed a $350 million strategic investment which included the sale of 350,000 shares of Senior Non-Convertible Preferred Stock and 30,833,333 warrants to purchase common stock.
  • This preferred stock carries an initial 14.5% dividend rate.
  • The number of shares outstanding for SelectQuote increased by 11.53% in one year, as of March 11, 2026.

Inbound Investments

  • SelectQuote received a $350 million strategic investment in February 2025 from funds managed by Bain Capital, Morgan Stanley Private Credit, and Newlight Partners.
  • This investment aimed to recapitalize the company's balance sheet, reduce annual debt service, and enhance liquidity to support future growth opportunities.

Outbound Investments

  • SelectQuote formed SelectQuote Ventures, Inc. (SVI) to strategically evaluate potential partnerships and acquisitions, with Express Med Pharmaceutical Inc. being its first acquisition in or prior to fiscal year 2021.
  • The company has strategically decided to rationalize its auto and home business by reducing agent headcount and external lead sourcing to reallocate capital to more cash-efficient parts of the business.

Capital Expenditures

  • SelectQuote reported capital expenditures of $1.1 million in Q2 2026.
  • Annual capital expenditures were $2.19 million in fiscal year 2025, $3.38 million in fiscal year 2024, and $1.45 million in fiscal year 2023.
  • The company's capital expenditures are primarily focused on funding long-term assets and infrastructure, with ongoing investments in technology and healthcare services contributing to efficiency and growth.

Better Bets vs. SelectQuote (SLQT)

Trade Ideas

Select ideas related to SLQT.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
EEFT_4302026_Dip_Buyer_ValueBuy04302026EEFTEuronet WorldwideDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin
0.0%0.0%0.0%
HOMB_4242026_Insider_Buying_GTE_1Mil_EBITp+DE_V204242026HOMBHome BancSharesInsiderInsider Buys | Low D/EStrong Insider Buying
Companies with strong insider buying in the last 1 month, positive operating income and reasonable debt / market cap
1.5%1.5%0.0%
HBAN_3312026_Insider_Buying_45D_2Buy_200K03312026HBANHuntington BancsharesInsiderInsider Buys 45DStrong Insider Buying
Companies with multiple insider buys in the last 45 days
7.1%7.1%0.0%
NP_3312026_Insider_Buying_45D_2Buy_200K03312026NPNeptune InsuranceInsiderInsider Buys 45DStrong Insider Buying
Companies with multiple insider buys in the last 45 days
3.9%3.9%0.0%
JKHY_3272026_Monopoly_xInd_xCD_Getting_Cheaper03272026JKHYJack Henry & AssociatesMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple
0.3%0.3%-4.0%
SLQT_8312021_Insider_Buying_GTE_1Mil_EBITp+DE_V208312021SLQTSelectQuoteInsiderInsider Buys | Low D/EStrong Insider Buying
Companies with strong insider buying in the last 1 month, positive operating income and reasonable debt / market cap
-70.7%-88.4%-88.4%

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

SLQTEHTHGOCOEVERLMNDHIPOMedian
NameSelectQu.eHealth GoHealth EverQuoteLemonade Hippo  
Mkt Price1.061.620.6818.6357.0525.9510.12
Mkt Cap0.20.10.00.74.40.70.4
Rev LTM1,642529153717845480623
Op Inc LTM5867-19574--63
FCF LTM-17-81-1089620401
FCF 3Y Avg-2-38-2759-43-21-24
CFO LTM-2-67-103102305314
CFO 3Y Avg11-25-1663-343-7

Growth & Margins

SLQTEHTHGOCOEVERLMNDHIPOMedian
NameSelectQu.eHealth GoHealth EverQuoteLemonade Hippo  
Rev Chg LTM10.3%-4.3%-81.7%24.5%51.2%20.8%15.5%
Rev Chg 3Y Avg21.7%13.0%-11.0%35.0%40.6%55.2%28.3%
Rev Chg Q5.6%-22.2%-94.6%14.5%70.6%10.2%7.9%
QoQ Delta Rev Chg LTM1.4%-4.5%-57.8%3.5%14.5%2.4%1.9%
Op Inc Chg LTM-27.2%35.9%-4,571.0%61.5%--4.4%
Op Inc Chg 3Y Avg116.2%163.0%-1,463.3%117.7%--117.0%
Op Mgn LTM3.5%12.7%-127.7%10.3%--6.9%
Op Mgn 3Y Avg3.8%6.0%-45.4%3.1%--3.4%
QoQ Delta Op Mgn LTM0.8%0.3%-85.4%0.7%--0.5%
CFO/Rev LTM-0.1%-12.6%-67.1%14.2%3.6%11.1%1.7%
CFO/Rev 3Y Avg0.7%-4.7%-19.7%10.4%-8.1%-1.9%-3.3%
FCF/Rev LTM-1.0%-15.3%-70.5%13.4%2.3%8.3%0.6%
FCF/Rev 3Y Avg-0.2%-7.2%-22.0%9.5%-9.7%-9.8%-8.4%

Valuation

SLQTEHTHGOCOEVERLMNDHIPOMedian
NameSelectQu.eHealth GoHealth EverQuoteLemonade Hippo  
Mkt Cap0.20.10.00.74.40.70.4
P/S0.10.10.10.95.21.40.5
P/Op Inc3.50.8-0.19.0--2.1
P/EBIT1.40.8-0.09.0--1.1
P/E2.21.5-0.06.1-31.36.01.8
P/CFO-88.2-0.8-0.16.6144.612.63.2
Total Yield45.8%66.2%-2,632.2%16.4%-3.2%16.8%16.6%
Dividend Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%
FCF Yield 3Y Avg-5.0%-72.9%-134.5%8.7%-3.6%-5.4%-5.2%
D/E2.02.662.50.00.00.11.0
Net D/E1.90.458.9-0.3-0.1-0.70.2

Returns

SLQTEHTHGOCOEVERLMNDHIPOMedian
NameSelectQu.eHealth GoHealth EverQuoteLemonade Hippo  
1M Rtn38.5%-11.5%-44.9%11.1%-13.6%-8.9%-10.2%
3M Rtn27.8%8.7%-59.2%29.3%-7.5%-9.0%0.6%
6M Rtn-20.9%-51.1%-70.5%-20.3%-16.1%-17.8%-20.6%
12M Rtn-52.0%-64.6%-88.7%-17.6%96.1%17.3%-34.8%
3Y Rtn-44.2%-78.4%-96.6%108.2%221.4%42.2%-1.0%
1M Excs Rtn23.8%-14.3%-50.1%9.4%-18.5%-14.2%-14.3%
3M Excs Rtn11.3%1.7%-65.9%12.5%-8.2%-16.4%-3.3%
6M Excs Rtn-40.4%-69.4%-83.6%-36.6%-29.8%-31.7%-38.5%
12M Excs Rtn-78.6%-91.0%-114.8%-46.6%54.2%-12.4%-62.6%
3Y Excs Rtn-100.9%-158.2%-176.2%91.6%203.0%-42.2%-71.5%

Comparison Analyses

null

Financials

Segment Financials

Revenue by Segment
$ Mil20252024202320222021
Senior656590528729362
Healthcare Services47925270  
Life158146154178130
All other3622283141
Eliminations of intersegment revenues-7-7-16-7-1
Total1,3221,003764930532


Price Behavior

Price Behavior
Market Price$1.06 
Market Cap ($ Bil)0.2 
First Trading Date05/21/2020 
Distance from 52W High-60.6% 
   50 Days200 Days
DMA Price$0.82$1.42
DMA Trenddownindeterminate
Distance from DMA29.6%-25.6%
 3M1YR
Volatility129.9%101.3%
Downside Capture465.50423.38
Upside Capture421.19212.32
Correlation (SPY)37.3%32.5%
SLQT Betas & Captures as of 4/30/2026

 1M2M3M6M1Y3Y
Beta1.892.603.262.802.041.90
Up Beta1.181.952.631.331.011.40
Down Beta-12.370.762.232.052.291.82
Up Capture396%374%319%330%139%1367%
Bmk +ve Days15223166141428
Stock +ve Days16243258104346
Down Capture407%303%354%270%200%113%
Bmk -ve Days4183056108321
Stock -ve Days6193264137371

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with SLQT
SLQT-53.1%101.4%-0.33-
Sector ETF (XLF)2.3%14.6%-0.0627.9%
Equity (SPY)26.8%12.1%1.6732.7%
Gold (GLD)37.5%26.8%1.167.9%
Commodities (DBC)43.5%18.6%1.80-9.5%
Real Estate (VNQ)12.0%13.4%0.5916.2%
Bitcoin (BTCUSD)-27.2%41.8%-0.6527.9%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with SLQT
SLQT-45.2%108.8%-0.04-
Sector ETF (XLF)8.3%18.6%0.3332.1%
Equity (SPY)13.8%17.0%0.6434.3%
Gold (GLD)19.3%18.0%0.872.6%
Commodities (DBC)10.8%19.4%0.446.1%
Real Estate (VNQ)3.8%18.8%0.1028.9%
Bitcoin (BTCUSD)9.3%55.6%0.3717.0%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with SLQT
SLQT-27.6%102.2%-0.05-
Sector ETF (XLF)12.7%22.2%0.5328.9%
Equity (SPY)15.5%17.9%0.7433.6%
Gold (GLD)13.2%16.0%0.683.2%
Commodities (DBC)7.8%17.9%0.356.2%
Real Estate (VNQ)5.4%20.7%0.2227.9%
Bitcoin (BTCUSD)67.3%66.9%1.0616.2%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date4302026
Short Interest: Shares Quantity5.0 Mil
Short Interest: % Change Since 4152026-2.9%
Average Daily Volume1.0 Mil
Days-to-Cover Short Interest5.2 days
Basic Shares Quantity189.5 Mil
Short % of Basic Shares2.7%

Earnings Returns History

Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
5/5/202652.4%27.8% 
2/5/2026-29.0%-39.3%-47.9%
11/6/2025-21.1%-23.9%-36.6%
8/21/202541.5%31.7%12.0%
5/12/2025-12.0%-14.2%-17.6%
2/10/202530.8%38.1%-17.4%
9/13/2024-43.7%-44.3%-37.6%
5/9/20243.6%17.6%13.2%
...
SUMMARY STATS   
# Positive997
# Negative111112
Median Positive11.4%27.8%13.2%
Median Negative-21.1%-23.9%-26.8%
Max Positive52.4%38.1%58.6%
Max Negative-47.3%-56.8%-59.6%

SEC Filings

Expand for More
Report DateFiling DateFiling
03/31/202605/05/202610-Q
12/31/202502/05/202610-Q
09/30/202511/06/202510-Q
06/30/202508/21/202510-K
03/31/202505/12/202510-Q
12/31/202402/10/202510-Q
09/30/202411/04/202410-Q
06/30/202409/13/202410-K
03/31/202405/09/202410-Q
12/31/202302/08/202410-Q
09/30/202311/03/202310-Q
06/30/202309/13/202310-K
03/31/202305/10/202310-Q
12/31/202202/07/202310-Q
09/30/202211/03/202210-Q
06/30/202208/29/202210-K

Recent Forward Guidance [BETA]

Latest: Q3 2026 Earnings Reported 5/5/2026

Forward GuidanceGuidance Change
MetricLowMidHigh% Chg% DeltaChangePrior
2026 Revenue1.61 Bil1.66 Bil1.71 Bil0 AffirmedGuidance: 1.66 Bil for 2026
2026 Adjusted EBITDA90.00 Mil95.00 Mil100.00 Mil0 AffirmedGuidance: 95.00 Mil for 2026

Prior: Q2 2026 Earnings Reported 2/5/2026

Forward GuidanceGuidance Change
MetricLowMidHigh% Chg% DeltaChangePrior
2026 Revenue1.61 Bil1.66 Bil1.71 Bil-2.4% LoweredGuidance: 1.70 Bil for 2026
2026 Adjusted EBITDA90.00 Mil95.00 Mil100.00 Mil-29.6% LoweredGuidance: 135.00 Mil for 2026

Insider Activity

Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Devine, Denise L DirectSell52120261.024,0004,080374,558Form
2Grant, Robert ClayPRESIDENTA. Grant Irrevocable TrustBuy21920260.8939,36634,99689,581Form
3Grant, Robert ClayPRESIDENTG. Grant Irrevocable TrustBuy21920260.8939,51435,00989,410Form
4Grant, Robert ClayPRESIDENTR. Grant Irrevocable TrustBuy21920260.8840,02135,01888,743Form